What is HC Wainwright’s Estimate for AMLX FY2030 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for Amylyx Pharmaceuticals in a research note issued on Monday, January 26th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of $1.70 for the year. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06.

A number of other analysts have also recently commented on the stock. Citigroup boosted their target price on shares of Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Bank of America boosted their price objective on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Robert W. Baird raised their target price on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Amylyx Pharmaceuticals Stock Performance

NASDAQ:AMLX opened at $15.47 on Tuesday. The stock has a market capitalization of $1.70 billion, a PE ratio of -8.59 and a beta of -0.31. Amylyx Pharmaceuticals has a fifty-two week low of $2.60 and a fifty-two week high of $17.49. The company has a fifty day moving average of $13.45 and a two-hundred day moving average of $12.06.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals in the second quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $45,000. BNP Paribas Financial Markets boosted its stake in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $47,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Amylyx Pharmaceuticals during the third quarter worth approximately $48,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Joshua B. Cohen sold 1,974 shares of Amylyx Pharmaceuticals stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.83, for a total transaction of $27,300.42. Following the sale, the chief executive officer owned 3,379,465 shares of the company’s stock, valued at $46,738,000.95. The trade was a 0.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Justin B. Klee sold 1,995 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the transaction, the chief executive officer owned 3,379,398 shares in the company, valued at $46,939,838.22. This represents a 0.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 157,783 shares of company stock valued at $2,122,808 over the last three months. Company insiders own 12.30% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.